Imbio PHA (4.0.0) vs PMcardio

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Imbio
VS
by Powerful Medical

AI Verdict

Tool A, Imbio PHA, specializes in analyzing CT pulmonary angiogram (CTPA) scans to assess cardiac structures and aid in diagnosing pulmonary embolism and hypertension. Tool B, PMcardio, focuses on interpreting ECGs to detect a wide range of cardiac conditions. While both tools contribute to cardiac care, their distinct input modalities (CTPA vs. ECG) and primary analytical targets make them complementary rather than direct competitors.

Choose Imbio PHA (4.0.0) if…

Choose Imbio PHA (4.0.0) if your primary need is the automated, quantitative assessment of cardiac structures from CT pulmonary angiogram (CTPA) scans. This tool excels at measuring right and left ventricle diameters, main pulmonary artery and aorta diameters, and calculating RV/LV and PA/Ao ratios to aid in diagnosing and risk stratifying pulmonary embolism and hypertension. It's ideal for radiologists and cardiologists who require rapid, standardized analysis of CTPA images to assess right ventricular dilation and integrate these findings into existing DICOM workflows.

View Imbio PHA (4.0.0) →

Choose PMcardio if…

Choose PMcardio if your focus is on rapid, AI-powered interpretation of electrocardiograms (ECGs) for a broad range of cardiac conditions at the point of care. This tool is particularly well-suited for emergency medicine, internal medicine, and cardiology professionals who need instant, expert-level ECG analysis to detect over 50 cardiac conditions, including STEMI/OMI and reduced LVEF. Its mobile app and web platform deployment, along with features like AI explainability and integration with EHR/CViS, make it valuable for quick clinical decision-making and bridging skills gaps in ECG interpretation.

View PMcardio →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Imbio PHA (4.0.0) PMcardio
Pricing Contact for pricing Freemium
Deployment Cloud, Enterprise (on-premise), or via partners Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems
FDA Status Yes AI-estimated Pending AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

PMcardio

PMcardio offers a mobile app and web platform, allowing clinicians to start using it immediately without IT integration. It emphasizes a user-friendly experience with instant AI-powered ECG interpretations and visual explainability. Imbio PHA, while automated, is integrated into existing PACS workflows, which might require more initial setup and familiarity with radiology systems.

Clinical Value

PMcardio

PMcardio is clinically validated in over 25 studies, detecting 50+ cardiac conditions, including STEMI/OMI and reduced LVEF, and has shown to reduce door-to-balloon times and false positive cath lab activations. Imbio PHA focuses on automated measurements from CTPA scans to assess right ventricular dilation for pulmonary embolism and hypertension, which is valuable but more narrowly focused.

Pricing & Value

PMcardio

PMcardio offers a freemium model with a free plan for individuals (5 free ECG analyses per month) and transparent pricing for its Pro plan. Imbio PHA requires direct contact for pricing, making its value proposition less transparent for potential users.

Enterprise Readiness

PMcardio

PMcardio is designed for enterprise deployment with integrations into EHR/CVIS and EMS systems, offering unified AI models, end-to-end pathway coverage, and robust security and compliance certifications (SOC 2 Type II, ISO 27001, GDPR, HIPAA). Imbio PHA offers deployment flexibility (cloud, on-premise, partners) and HIPAA compliance, but PMcardio's explicit focus on comprehensive enterprise integration and care coordination across multiple pathways gives it an edge.

Innovation

PMcardio

PMcardio demonstrates broader innovation by interpreting ECGs for over 50 cardiac conditions, including advanced features like Queen of Heartsu2122 for STEMI/OMI detection, LVsenseu2122 for reduced LVEF, and ECGxplainu2122 for visual AI explainability. Imbio PHA's innovation lies in its automated measurement of cardiac structures from CTPA scans, which is a specialized application of AI in imaging.

Support & Docs

Tie

Both tools provide documentation and support. PMcardio offers a Help Center with articles on getting started, using the app, and FAQs, along with regulatory and security information. Imbio PHA's documentation includes user manuals and information on clinical performance validation. Without more detailed information on the breadth and responsiveness of their support channels, it's difficult to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Imbio PHA (4.0.0) PMcardio
Tool Name Imbio PHA (4.0.0) PMcardio
Description FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately. Clinically validated in more than 25 studies and trusted by over 100,000 clinicians, it delivers rapid, expert-level interpretations, empowering various healthcare professionals to act with confidence at the point of care.
Company Imbio Powerful Medical
Regulatory Clearance FDA-cleared CE-certified
Key Features Automated measurement of right and left ventricle diameters; Automated measurement of main pulmonary artery and aorta diameters; Calculates RV/LV and PA/Ao ratios; Utilizes artificial intelligence algorithms for anatomical identification and measurement; Generates annotated DICOM images; Provides summary reports in PDF format; Integrates with native DICOM tools and workflows; Rapid, fully-automated assessment (typically in minutes) Instant AI-powered ECG interpretations; Detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders); Queen of Heartsu2122 - STEMI and OMI Detection; LVsenseu2122 - Reduced LVEF Detection; ECGxplainu2122 - Visual AI Explainability with heatmaps; Core AI - Detects 36 core diagnoses (arrhythmias, conduction blocks, heart blocks, chamber hypertrophies); Automatic analysis of heart rate, axis, P wave, PR, QRS, and QT/QTc intervals; Culprit Artery AI confidence scores with 3D heart visualization
Specialties Cardiology, Pulmonology, Radiology Cardiology, Emergency Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and PMcardio.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Imbio PHA integrates with native DICOM tools and workflows, generating annotated DICOM images and PDF summary reports. PMcardio offers broader integration capabilities, connecting to existing ECG systems, EHR/CVIS, EMS systems, angiographic systems, and communication tools, with automated ECG format recognition for streamlined workflows.
Imbio PHA has been validated to be accurate in measuring RV/LV and PA/Ao ratios, with 97% of RV/LV ratios within the limits of agreement with expert radiologists. PMcardio has been clinically validated in over 25 studies, demonstrating 86% sensitivity and 92% specificity for major ECG abnormalities, and 97% sensitivity and 99% specificity for Atrial Fibrillation.
Imbio PHA is designed for rapid, fully-automated assessment, typically in minutes, suggesting a low learning curve for its specific measurements. PMcardio aims to ease the learning curve with a brief guide for successful ECG digitization, including matching ECG pictograms and ensuring horizontal positioning of leads.
PMcardio offers email/help desk support for customer questions and issue reporting. Imbio's support details are not explicitly provided in the given information, but generally, enterprise solutions like Imbio PHA would offer dedicated support for implementation and ongoing use.
PMcardio for Organizations includes audit logs and offers dashboards and reporting to support QA, audits, protocol optimization, and registry compliance. Imbio PHA's documentation mentions generating summary reports in PDF format and annotated DICOM images, which can contribute to an audit trail, but specific audit log features are not detailed.
Imbio PHA aids in the diagnosis and risk stratification of pulmonary embolism and hypertension by measuring cardiac structures and calculating RV/LV and PA/Ao ratios. PMcardio provides instant AI-powered ECG interpretations for over 50 cardiac conditions, including STEMI/OMI and reduced LVEF, and offers in-app Patient Management Recommendations based on ESC guidelines, using a traffic-light triage system.

Backers

Who funded each tool's parent company.

PMcardio

AI Tool Finder
AI-powered search. Results may not be comprehensive.